AI reshapes small nucleic acid innovation, the next generation of big drugs is brewing
Interview with Jingtai Technology Gao Xiangrui.
Time：
2026-07-31 18:20
Author：
xieyijun
CPIC 2026 | What determines the pricing of innovative drug BD in China?
Maximizing the Value of Innovative Drugs in China
Time：
2026-07-30 18:41
Author：
xieyijun
CPIC 2026 | Ma Jun: Where has China CGT gone?
Time：
2026-07-29 20:32
Author：
xieyijun
CPIC 2026丨AI pharmaceuticals have no finale
Time：
2026-07-28 17:23
Author：
xieyijun
Tonacea Launches Self-Discipline Convention Endorsed by Nearly 100 CGT Companies
Taking events as a mirror and promoting development through self-discipline
Time：
2026-07-28 17:13
Author：
xieyijun
CPIC 2026 | Dialogue with Zhu Yi: Whatever Keytruda Can Sell, We Can Sell Too
One dares to ask, the other dares to answer.
Time：
2026-07-25 17:19
Author：
xieyijun
The Chinese Chessboard of MNCs Has Changed.
From a Single Market to an Innovation Hub
Time：
2026-07-19 09:16
Author：
xieyijun
A medicine bottle, carrying the dream of overseas expansion for domestic pharmaceutical packaging
The Past, Present, and Future of Zhengchuan Co., Ltd
Time：
2026-07-18 08:23
Author：
xieyijun
Recommended content
mRNA tumor vaccine "seller", entering a golden age
When a Biotech company that has been acquired achieves rare growth
AI、 Cold bench and puzzle, when will 'one person, one seedling' come to an end?
This road is long, but the threshold has already been crossed.
The "economic accounts" of immunology business development are being rewritten
After rejecting a $30 billion acquisition offer, a biotech company has emerged as a giant
determination for independence
联系我们
同写意
写意宣发
同写意Biotech
同写意微服务